Skip to main content

Table 2 Outcomes of patients with and without sepsis*

From: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial

  Patients with sepsis Patients without sepsis
Outcome variable DEX (n = 31) LZ
(n = 32)
Adjusted P value** DEX
(n = 20)
LZ (n = 19) Adjusted
P value**
Duration of brain organ dysfunction       
Delirium/coma-free days** 6.1 (4.3) 2.9 (3.2) 0.005 6 (4.7) 5.5 (3.6) 0.97
Delirium-free days 8.1 (3.1) 6.7(2.9) 0.06 8.1 (3.5) 7.9 (2.8) 0.80
Coma-free daysǂ 9.4 (2.9) 5.9 (4.2) <0.001 8.9 (4) 8.8 (2.6) 1
Other clinical outcomes       
MV-free days 15.2 (10.6) 10.1 (10.3) 0.03 12.8 (11.5) 17.2 (10) 0.15
ICU days 13.4 (15.1) 12.2 (9.8) 0.81 14.9 (16.5) 10.4 (8.9) 0.28
28-day mortality 16% 41% 0.03 19% 5% 0.21
  1. Mean (standard deviation) unless otherwise noted.
  2. DEX, dexmedetomidine; LZ, lorazepam; MV, mechanical ventilation.
  3. * Adjusted P value obtained from the bootstrap multiple linear regression that calculated a difference in mean for each outcome between the two treatment groups, adjusting for age, severity of illness, use of drotrecogin alfa (activated) within 48 hours of enrollment, sepsis, treatment group, and a treatment group by sepsis interaction.
  4. **Indicates the number of days alive without delirium or coma from study day 1 to 12.
  5. †Indicates the number of days alive without delirium from study day 1 to 12.
  6. ǂIndicates the number of days alive without coma from study day 1 to 12.
  7. ‡Indicates the number of days alive breathing without assistance of the ventilator from study day 1 to 28.